

Public Health Evidence Report Following Engagement Activity

This form is to be completed by the Policy Working Groups Public Health Lead if stakeholders identify potential new evidence during policy development engagement activities. The Public Health Lead will assess the evidence raised to against the Population, Intervention, Comparator and Outcome (PICO) criteria and will record the studies in the appropriate boxes in the '*Outcome for studies suggested during engagement activities*' section of this form. In cases where newly identified evidence has a material impact please return the completed form to the Clinical Effectiveness Team (CET).

URN	2331
Policy title:	Osilodrostat phosphate for adult patients with endogenous Cushing's syndrome
CRG:	Specialised Endocrinology
NPOC:	Internal Medicine
Engagement activity	Stakeholder engagement
Date	

Description of comments during engagement (If studies have been suggested please provide a list of references)	Stakeholder comment:- In addition to the pivotal LINC 3 and LINC 4 studies, and their extension phases which were included in the Cushing's disease evidence review, a posthoc analysis of the LINC 3 study was published after the evidence review cut-off date (Pivonello et al. J Endocrinol Invest. 2024. doi: 10.1007/s40618-024-02359-62024). This publication evaluated mUFC, cardiometabolic parameters (such as blood pressure, bodyweight, waist circumference, BMI, lipid profiles, and glycaemic status), physical manifestations of hypercortisolism (such as fat pads, central obesity, rubor, striae, and hirsutism in women), and HRQoL. These data further support the benefits of osilodrostat treatment beyond the rapid and sustained normalisation of cortisol. Overall, mean improvements from Baseline in cardiometabolic parameters at Week 24 were greater in patients
---	---

	with controlled or partially controlled versus uncontrolled mUFC; at Week 48, improvements occurred irrespective of mUFC control. Generally, physical manifestations and QoL progressively improved from Baseline irrespective of mUFC control.
Action taken by Public Health lead	Receipt of additional evidence submitted by stakeholder during engagement, review and completion of this form.

Outcome for studies suggested during engagement activities

1. Evidence already identified during the evidence review	Not applicable
2.New evidence identified by stakeholders that does not fall within PICO and search methodology	Not applicable
3.New evidence identified by stakeholders that falls within PICO and search methodology but does not materially affect the conclusions of the existing evidence review	In summary, the new evidence is additional reporting of the LINC3 study (n=137) which was published in 2024, outside of the parameters of the original evidence review which included studies published between 2013-2023. The additional evidence strengthens the conclusions of the existing evidence review.
4.New evidence identified by stakeholders that falls within PICO and search methodology, that does materially affect the conclusions of the existing evidence review. Updated evidence review to be undertaken (to be agreed with CET)	Not applicable

Completed by:	Public Health Consultant
Date:	16/09/2024

Peer reviewed and supported by:	
---------------------------------	--

Date:	
-------	--